Precision BioSciences, Inc.
(NASDAQ : DTIL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 16.35%127.030.0%$2227.08m
BIIBBiogen, Inc. 0.84%243.781.7%$657.15m
AMGNAmgen, Inc. 2.04%224.811.3%$567.96m
GILDGilead Sciences, Inc. 0.89%60.031.0%$514.37m
NVAXNovavax, Inc. 22.51%125.6992.9%$508.55m
BNTXBioNTech SE 4.79%109.990.0%$483.37m
VRTXVertex Pharmaceuticals, Inc. 3.95%226.711.9%$475.11m
REGNRegeneron Pharmaceuticals, Inc. 1.13%514.052.7%$473.60m
ILMNIllumina, Inc. 4.29%317.033.5%$393.59m
APVOAptevo Therapeutics, Inc. 1.32%44.3918.3%$233.60m
SGENSeagen Inc. 2.22%169.125.8%$182.62m
EXASEXACT Sciences Corp. 2.00%118.1919.6%$179.47m
ALXNAlexion Pharmaceuticals, Inc. 0.73%123.832.0%$157.60m
HALOHalozyme Therapeutics, Inc. -2.21%40.2318.4%$131.67m
SRNESorrento Therapeutics, Inc. 18.12%8.151.4%$127.58m

Company Profile

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.